Danaher Co. (NYSE:DHR) Position Boosted by Busey Bank

Busey Bank raised its holdings in shares of Danaher Co. (NYSE:DHR) by 2.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,698 shares of the conglomerate’s stock after acquiring an additional 2,254 shares during the period. Busey Bank’s holdings in Danaher were worth $22,656,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Decker Retirement Planning Inc. bought a new position in Danaher during the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher during the third quarter worth about $40,000. FSA Wealth Management LLC bought a new stake in Danaher in the third quarter worth about $50,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Danaher in the 3rd quarter worth approximately $55,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on DHR shares. Raymond James cut their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday, December 13th. Jefferies Financial Group cut their price objective on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $282.48.

Danaher Stock Down 10.0 %

DHR stock opened at $223.12 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a market cap of $161.16 billion, a PE ratio of 42.58, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a 1 year low of $223.00 and a 1 year high of $281.70. The company has a fifty day simple moving average of $236.09 and a 200 day simple moving average of $253.66.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter in the prior year, the firm posted $2.09 earnings per share. Sell-side analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.48%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.